BibTex RIS Kaynak Göster

The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin

Yıl 2012, , 121 - 123, 01.09.2012
https://doi.org/10.5799/ahinjs.02.2012.03.0056

Öz

Hayati Demiraslan, Zeynep Ture, Aysegul Ulu Kılıc The pegylated interferon alpha and ribavirin treatment is well established therapy for hepatitis C virus (HCV) infection. During the treatment alanine aminotransferase (ALT) lare may be observed rarely. A 51-year-old female receiving pegylated interferon and ribavirin therapy for HCV infection, complained nausea, vomit- ing in seventh week of the therapy, and her ALT level was detected over 20 times above the normal level. Hepatitis B sur- face antigen, anti-nuclear antibody, anti-mitochondrial antibody, anti-double stranded DNA antibody and anti-hepatitis A virus IgM antibody were negative, and thyroid stimulating hormone was normal. HCV RNA level was 424 IU/ml. PEG IFN and ribavirin therapy was interrupted for three weeks, after liver enzyme level was detected less than 100U/L, the treatment was resumed. The patient was followed up for 2 months, ALT lare was not observed. In conclusion, we present a rare case with ALT lare, while receiving pegylated interferon and ribavirin therapy for chronic HCV infection.

Kaynakça

  • Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis c virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31 Suppl 2:30-60.
  • Calvaruso V, Craxi A. 2011 European Association of The Study of The Liver Hepatitis C Virus Clinical Practice Guidelines. Liver Int 2012; 32 Suppl 1:2-8.
  • Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hep- atology 2009; 49:1335-1374.
  • Amarapurkar DN. Flares on and off therapy during chronic hbv infection: Pathogenesis, significance and management. Hep B Annual 2008;5:12-22.
  • Demiraslan H, Aygen B, Yildiz O, Soyuer I, Gokahmetoglu S. Kronik hepatit C tedavisinde interferon-α 2a+ ribavirin ile peginterferon-α 2a ribavirin kombinasyonlarının karşılaştırıl- ması. Viral Hepatit Dergisi 2008;13:12-22.
  • Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis b patients induced by the host or the virus? Re- lation to treatment response during peg-interferon alpha-2b therapy. Gut 2005;54:1604-1609.
  • Parana R, Schinoni MI, de Freitas LA, et al. Anti-golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver Int 2006;26:1148-1154.
  • Yalcin K, Degertekin H, Yildiz F, Kilinc N. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 2003;38:796-800.
  • Mishra P, DeVoss A, Pai R, Hart J, Jensen DM. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: A case report. Dig Dis Sci 2009; 54:1369-1372.

The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin

Yıl 2012, , 121 - 123, 01.09.2012
https://doi.org/10.5799/ahinjs.02.2012.03.0056

Öz

Kaynakça

  • Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis c virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31 Suppl 2:30-60.
  • Calvaruso V, Craxi A. 2011 European Association of The Study of The Liver Hepatitis C Virus Clinical Practice Guidelines. Liver Int 2012; 32 Suppl 1:2-8.
  • Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hep- atology 2009; 49:1335-1374.
  • Amarapurkar DN. Flares on and off therapy during chronic hbv infection: Pathogenesis, significance and management. Hep B Annual 2008;5:12-22.
  • Demiraslan H, Aygen B, Yildiz O, Soyuer I, Gokahmetoglu S. Kronik hepatit C tedavisinde interferon-α 2a+ ribavirin ile peginterferon-α 2a ribavirin kombinasyonlarının karşılaştırıl- ması. Viral Hepatit Dergisi 2008;13:12-22.
  • Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis b patients induced by the host or the virus? Re- lation to treatment response during peg-interferon alpha-2b therapy. Gut 2005;54:1604-1609.
  • Parana R, Schinoni MI, de Freitas LA, et al. Anti-golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver Int 2006;26:1148-1154.
  • Yalcin K, Degertekin H, Yildiz F, Kilinc N. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 2003;38:796-800.
  • Mishra P, DeVoss A, Pai R, Hart J, Jensen DM. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: A case report. Dig Dis Sci 2009; 54:1369-1372.
Toplam 9 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Bölüm Olgu Sunumu
Yazarlar

Hayati Demiraslan Bu kişi benim

Zeynep Ture Bu kişi benim

Aysegul Ulu Kılıc Bu kişi benim

Yayımlanma Tarihi 1 Eylül 2012
Yayımlandığı Sayı Yıl 2012

Kaynak Göster

APA Demiraslan, H., Ture, Z., & Kılıc, A. U. (2012). The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin. Journal of Microbiology and Infectious Diseases, 2(03), 121-123. https://doi.org/10.5799/ahinjs.02.2012.03.0056
AMA Demiraslan H, Ture Z, Kılıc AU. The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin. J Microbil Infect Dis. Eylül 2012;2(03):121-123. doi:10.5799/ahinjs.02.2012.03.0056
Chicago Demiraslan, Hayati, Zeynep Ture, ve Aysegul Ulu Kılıc. “The Acute Hepatic Flare in a Patient With Chronic Hepatitis C Infection Receiving Pegylated Interferon Alpha 2b and Ribavirin”. Journal of Microbiology and Infectious Diseases 2, sy. 03 (Eylül 2012): 121-23. https://doi.org/10.5799/ahinjs.02.2012.03.0056.
EndNote Demiraslan H, Ture Z, Kılıc AU (01 Eylül 2012) The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin. Journal of Microbiology and Infectious Diseases 2 03 121–123.
IEEE H. Demiraslan, Z. Ture, ve A. U. Kılıc, “The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin”, J Microbil Infect Dis, c. 2, sy. 03, ss. 121–123, 2012, doi: 10.5799/ahinjs.02.2012.03.0056.
ISNAD Demiraslan, Hayati vd. “The Acute Hepatic Flare in a Patient With Chronic Hepatitis C Infection Receiving Pegylated Interferon Alpha 2b and Ribavirin”. Journal of Microbiology and Infectious Diseases 2/03 (Eylül 2012), 121-123. https://doi.org/10.5799/ahinjs.02.2012.03.0056.
JAMA Demiraslan H, Ture Z, Kılıc AU. The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin. J Microbil Infect Dis. 2012;2:121–123.
MLA Demiraslan, Hayati vd. “The Acute Hepatic Flare in a Patient With Chronic Hepatitis C Infection Receiving Pegylated Interferon Alpha 2b and Ribavirin”. Journal of Microbiology and Infectious Diseases, c. 2, sy. 03, 2012, ss. 121-3, doi:10.5799/ahinjs.02.2012.03.0056.
Vancouver Demiraslan H, Ture Z, Kılıc AU. The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin. J Microbil Infect Dis. 2012;2(03):121-3.